Cell Source Inc
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of ly… Read more
Cell Source Inc (CLCS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.034x
Based on the latest financial reports, Cell Source Inc (CLCS) has a cash flow conversion efficiency ratio of 0.034x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-639.01K) by net assets ($-18.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cell Source Inc - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Cell Source Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cell Source Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cell Source Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inswave Systems Co., Ltd.
KQ:450520
|
-0.049x |
|
Choice Development Inc
TW:9929
|
0.058x |
|
Barrister Energy LLC
PINK:CJAX
|
-0.003x |
|
TVI Pacific Inc
PINK:TVIPF
|
0.000x |
|
EURO MANGANESE CDI/1
F:E06A
|
N/A |
|
Hammer Metals Limited
F:6HM
|
-0.006x |
|
Pinnacle Bancshares Inc
PINK:PCLB
|
0.043x |
|
Procorp S.A.B. de C.V
MX:PROCORPB
|
0.018x |
Annual Cash Flow Conversion Efficiency for Cell Source Inc (2012–2023)
The table below shows the annual cash flow conversion efficiency of Cell Source Inc from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-15.61 Million | $-2.35 Million | 0.150x | -39.46% |
| 2022-12-31 | $-12.63 Million | $-3.14 Million | 0.248x | -27.75% |
| 2021-12-31 | $-9.83 Million | $-3.38 Million | 0.344x | -1.51% |
| 2020-12-31 | $-7.95 Million | $-2.77 Million | 0.349x | -22.52% |
| 2019-12-31 | $-5.74 Million | $-2.59 Million | 0.451x | -10.24% |
| 2018-12-31 | $-4.56 Million | $-2.29 Million | 0.502x | 0.00% |
| 2017-12-31 | $-4.56 Million | $-2.29 Million | 0.502x | +109.76% |
| 2016-12-31 | $-6.24 Million | $-1.49 Million | 0.239x | -31.12% |
| 2015-12-31 | $-5.76 Million | $-2.00 Million | 0.347x | -57.86% |
| 2014-12-31 | $-3.78 Million | $-3.12 Million | 0.824x | +139.94% |
| 2013-12-31 | $11.33K | $-23.38K | -2.065x | -2179.83% |
| 2012-12-31 | $16.95K | $-1.54K | -0.091x | -- |